MX1 and idiopathic pulmonary fibrosis: We excluded five anti-ARS autoantibody–positive patients from the subsequent analysis and compared survival between anti-MX1 autoantibody–positive non-IPF (n = 20) and –negative non-IPF (n = 59) (Fig. 1C).